Master Alliance Provisions Guide (MAPGuide)

AbbVie-MPP License Agreement

  • IP ownership & licensing | Sublicenses

3. Sublicense

3.1 Form of Sublicense. MPP shall not grant sublicenses other than in the form of the Sublicense.

3.2 Sublicensee Identification. The parties intend that MPP will identify potential manufacturers of pharmaceutical products with a view to enter into Sublicenses. Upon identification of such a manufacturer, in each case, MPP shall provide notice to AbbVie of the identity of the manufacturer (including the name, address, principal place of business, list of affiliated entities) and any additional information that may be at the time reasonably requested by AbbVie.

3.3 Sublicensee Certification. MPP shall only enter into sublicenses with entities that have produced reasonable evidence demonstrating (i) their intent and capability to comply with applicable laws relating to corruption (including anti-bribery laws and the U.S. Foreign Corrupt Practices Act and the U.K. Bribery Act 2010) and (ii) where such licensee obtains the right to manufacture Licensed Compounds or Licensed Products, their capability to engage in such manufacture in a manner consistent with (a) World Health Organization pre-qualification standards; or (ii) the standards of any applicable regulatory authority which are members, observers or associates of the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use.